Clinical trial NCT00726583: Phase I Trial of Oral PX-866
Official title: A Phase I Trial of Oral PX-866 (a PI-3K Inhibitor) in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Solid Tumors
Keywords: Cancer
Solid Tumors
Carcinoma
PI-3K
PI3 kinase
PI3K
Lead sponsor: Seagen Inc.
Sponsor class: INDUSTRY
First posted: 2008-08-01
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is being conducted to determine the safety and maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.

Detailed description: PX-866 is a targeted inhibitor of PI-3K. This study is being conducted to determine the maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of advanced solid tumor and has failed or is intolerant of standard therapy, or for whom standard therapy does not exist.
* 18 years of age or older.
* ECOG performance status 0 to 1.
* Predicted life expectancy of at least 12 weeks.
* Discontinued prior chemotherapy or other investigational agents for at least three weeks prior to receiving the first dose of study drug (six weeks for mitomycin C, nitrosureas,vaccines,or antibody therapy)and recovered from the toxic effects of the prior treatment (recovered to baseline or ≤grade 1 per Common Toxicity Criteria for Adverse Events (CTCAE)).
* Discontinued any radiation therapy for at least four weeks and have recovered from all radiation-related toxicities (recovered to baseline or ≤CTCAE grade 1) prior to receiving the first dose of study drug. Palliative radiation of 10 fractions or less is permitted and a four week interval is not necessary (also allowed during therapy).
* Adequate hematologic function as defined by the following: WBC count \>3,000 cells/μL; platelets \>100,000/μL; hemoglobin \>9 g/dL (may be transfused to this level); ANC \>1500 cells/μL.
* Adequate hepatic function as defined by the following: bilirubin \<1.5 mg/dL; aspartate aminotransaminase (AST/SGOT) \& alanine aminotransferase (ALT/SGPT) \<2.5 x ULN or \<5 x ULN if due to metastatic disease.
* Adequate renal function as defined by serum creatinine level \<1.5 mg/dL.

Exclusion Criteria:

* Any active infection at study entry.
* Known diabetes or fasting blood glucose\>160 mg/dL.
* Known human immunodeficiency virus (HIV).
* Any serious concomitant systemic disorders that in the opinion of the investigator would place the patient at excessive or unacceptable risk of toxicity.
* Surgery within the four weeks prior to the first dose
* Significant central nervous system (CNS) or psychiatric disorder(s) that preclude the ability of the patient to provide informed consent.
* Known or suspected brain metastases that have not received adequate therapy or for which the patient requires treatment with steroids or anticonvulsants. In the case of previously treated brain metastases, a minimum four week interval between completion of radiation therapy and registration on study with radiologic evidence of stable or responding brain metastases is required. In the setting of previous CNS metastasectomy, adequate (minimum four week) recovery from surgery and/or radiation therapy should be documented.
* Leptomeningeal brain metastases should be excluded regardless of whether the metastases have been treated or not.
* History of seizures, non-healing wounds, or arterial thrombosis.
* Unstable atrial or ventricular arrhythmias requiring control by medication; any cardiac ischemic event experienced within the preceding six months; prior history of congestive heart failure requiring therapy.
* Breastfeeding or pregnant (confirmed by serum β-HCG within 10 days prior to the start of study treatment if applicable).
* Total gastrectomy, partial bowel obstruction or any gastrointestinal condition that may interfere with absorption of the study medication.
* Any condition that could jeopardize the safety of the patient and compliance with the protocol.

Primary outcomes:
measure: Determine the MTD of PX-866
timeFrame: 28 days
measure: Evaluate the safety profile of PX-866
timeFrame: 28 days
measure: Evaluate pharmacodynamic measures of the effects of PX-866 on the phosphatidylinositol-3 kinase (PI-3K) pathway and related tumor markers.
timeFrame: 28 days
measure: Determine the PK profile of PX-866.
timeFrame: 28 days
Secondary outcomes:
measure: Evaluate the anti-tumor activity of PX-866 in patients with advanced malignancies.
timeFrame: 56 days
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Health Sciences Center
state: Colorado
city: Houston
country: United States
facility: M.D. Anderson Cancer Center
state: Texas
Study officials:
References: